• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Genmab A/S ADR (NQ: GMAB )

    22.18 -0.57 (-2.53%)
    Streaming Delayed Price Updated: 9:36 AM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Genmab A/S ADR

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
    From Genmab A/S
    Via Business Wire
    Preview: Genmab's Earnings
    Via Benzinga
    NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
    Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation. 
    Via Chartmill
    When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
    GENMAB A/S -SP ADR (NASDAQ:GMAB) appears to be flying under the radar despite its strong fundamentals. 
    Via Chartmill
    Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
    GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing good growth, while it is not too expensive. 
    Via Chartmill
    12 Analysts Have This To Say About Genmab
    Via Benzinga
    NASDAQ:GMAB qualifies as a high growth stock and is consolidating.
    GENMAB A/S -SP ADR (NASDAQ:GMAB)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
    Via Chartmill
    NASDAQ:GMAB is an undervalued gem with solid fundamentals.
    Don't overlook GENMAB A/S -SP ADR (NASDAQ:GMAB)—it's a hidden gem with strong fundamentals and an attractive price tag. 
    Via Chartmill
    NASDAQ:GMAB, a growth stock which is not overvalued.
    NASDAQ:GMAB is showing good growth, while it is not too expensive. 
    Via Chartmill
    Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    NASDAQ:GMAB is probably undervalued for the fundamentals it is displaying.
    GENMAB A/S -SP ADR (NASDAQ:GMAB) is an undervalued gem with solid fundamentals. 
    Via Chartmill
    Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
    Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. 
    Via Chartmill
    Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
    From Genmab A/S
    Via Business Wire
    Expert Ratings For Genmab
    Via Benzinga
    NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
    Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock? 
    Via Chartmill
    NASDAQ:GMAB is showing good growth, while it is not too expensive.
    GENMAB A/S -SP ADR (NASDAQ:GMAB) is not too expensive for the growth it is showing. 
    Via Chartmill
    Decoding 10 Analyst Evaluations For Genmab
    Via Benzinga
    TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
    From Genmab A/S
    Via Business Wire
    Genmab Announces Changes to its Executive Committee
    From Genmab A/S
    Via Business Wire
    On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session
    Via Benzinga
    Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
    Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation. 
    Via Chartmill
    What 8 Analyst Ratings Have To Say About Genmab
    Via Benzinga
    GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024
    GMAB stock results show that Genmab missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
    BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology... 
    Via Benzinga
    Exposures COVID-19
    While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
    While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. 
    Via Chartmill
    What 8 Analyst Ratings Have To Say About Genmab
    Via Benzinga
    Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
    GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing decent growth, but is still valued reasonably. 
    Via Chartmill
    NASDAQ:GMAB, an undervalued stock with good fundamentals.
    GENMAB A/S -SP ADR (NASDAQ:GMAB) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
    Via Chartmill
    Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
    From Genmab A/S
    Via Business Wire
    AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
    The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. 
    Via Benzinga
    Exposures Product Safety
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.